Arabic Arabic English English French French German German
dark

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

Ascletis Pharma Inc. announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B indication. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console

Next Post

Why Marijuana is Being Used for Health Benefits

Related Posts
Total
0
Share